AVEO Pharmaceuticals, Inc. (AVEO) Major Shareholder Equity Opportunities Iv Growth Purchases 96,400 Shares

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) major shareholder Equity Opportunities Iv Growth acquired 96,400 shares of the firm’s stock in a transaction dated Friday, November 30th. The stock was bought at an average price of $1.98 per share, with a total value of $190,872.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Equity Opportunities Iv Growth also recently made the following trade(s):

  • On Monday, November 19th, Equity Opportunities Iv Growth acquired 1,200,000 shares of AVEO Pharmaceuticals stock. The stock was bought at an average price of $1.86 per share, with a total value of $2,232,000.00.

Shares of AVEO traded up $0.06 during midday trading on Friday, hitting $2.07. The company had a trading volume of 3,360,241 shares, compared to its average volume of 3,596,023. The stock has a market capitalization of $251.95 million, a PE ratio of -12.94 and a beta of 2.00. AVEO Pharmaceuticals, Inc. has a 1 year low of $1.49 and a 1 year high of $3.59.

AVEO Pharmaceuticals (NASDAQ:AVEO) last announced its quarterly earnings data on Friday, November 9th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.01. The company had revenue of $2.47 million during the quarter, compared to analysts’ expectations of $0.68 million. Research analysts forecast that AVEO Pharmaceuticals, Inc. will post -0.23 EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Birchview Capital LP raised its position in shares of AVEO Pharmaceuticals by 20.0% during the 3rd quarter. Birchview Capital LP now owns 120,000 shares of the biopharmaceutical company’s stock worth $397,000 after acquiring an additional 20,000 shares in the last quarter. Granahan Investment Management Inc. MA raised its position in shares of AVEO Pharmaceuticals by 16.3% during the 2nd quarter. Granahan Investment Management Inc. MA now owns 179,512 shares of the biopharmaceutical company’s stock worth $406,000 after acquiring an additional 25,134 shares in the last quarter. Bank of New York Mellon Corp raised its position in shares of AVEO Pharmaceuticals by 14.9% during the 3rd quarter. Bank of New York Mellon Corp now owns 331,010 shares of the biopharmaceutical company’s stock worth $1,096,000 after acquiring an additional 42,937 shares in the last quarter. X Square Capital LLC raised its position in shares of AVEO Pharmaceuticals by 18.9% during the 3rd quarter. X Square Capital LLC now owns 284,425 shares of the biopharmaceutical company’s stock worth $942,000 after acquiring an additional 45,190 shares in the last quarter. Finally, Creative Planning acquired a new stake in shares of AVEO Pharmaceuticals during the 2nd quarter worth about $143,000. 49.77% of the stock is currently owned by institutional investors and hedge funds.

Several equities analysts have recently issued reports on AVEO shares. BidaskClub upgraded AVEO Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, September 11th. HC Wainwright set a $9.00 price objective on AVEO Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, November 6th. Zacks Investment Research upgraded AVEO Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.25 price objective for the company in a research note on Monday, November 12th. Finally, National Securities cut AVEO Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Tuesday, November 6th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $5.42.

ILLEGAL ACTIVITY NOTICE: “AVEO Pharmaceuticals, Inc. (AVEO) Major Shareholder Equity Opportunities Iv Growth Purchases 96,400 Shares” was originally reported by Markets Daily and is owned by of Markets Daily. If you are accessing this report on another publication, it was copied illegally and republished in violation of United States and international copyright and trademark legislation. The original version of this report can be read at https://www.themarketsdaily.com/2018/12/01/aveo-pharmaceuticals-inc-aveo-major-shareholder-equity-opportunities-iv-growth-purchases-96400-shares.html.

About AVEO Pharmaceuticals

AVEO Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC).

Featured Story: Hedge Funds – Risk or Reward?

Insider Buying and Selling by Quarter for AVEO Pharmaceuticals (NASDAQ:AVEO)

Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply